Chiltern International is a global contract research organization (CRO) that provides comprehensive research and development solutions to the pharmaceutical, biotechnology, and medical device industries. With its headquarters in Wilmington, Massachusetts, United States, the company was founded in 1982 by Glenn Kerkhof and Dr. Susan Johnston.

Chiltern International offers a wide range of services, including clinical development, data management, biostatistics, medical writing, regulatory affairs, pharmacovigilance, and quality assurance. The company has a strong global presence, with offices and operations in over 50 countries across North America, Europe, Asia, and Latin America. The CRO has several noteworthy subsidiaries, joint ventures, and partnerships.

In 2017, Chiltern International merged with Theorem Clinical Research, expanding its service offerings and strengthening its global footprint. The merger enhanced Chiltern’s capabilities in medical device research and expanded its presence in Japan. Chiltern International is a leading player in the global CRO market.

The company has a strong market position, particularly in terms of global sales. It competes with other major CROs such as QuintilesIMS, Covance, and PPD for market share. Over the years, Chiltern International has achieved many notable milestones.

In 2015, the company was recognized as the “Best Contract Research Organization” at the Vaccine Industry Excellence (ViE) Awards. It has also been praised for its strong client relationships, quality service delivery, and operational excellence. As of the latest available updates, Chiltern International continues to thrive as a leading CRO.

The company focuses on driving innovation and expanding its service offerings to meet the evolving needs of the life sciences industry. Chiltern International's commitment to delivering high-quality research and development solutions remains unwavering, allowing the company to continuously grow and maintain its position in the global market